An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures"
- PMID: 25752764
- DOI: 10.1007/s10822-015-9835-6
An SH2 domain model of STAT5 in complex with phospho-peptides define "STAT5 Binding Signatures"
Abstract
The signal transducer and activator of transcription 5 (STAT5) is a member of the STAT family of proteins, implicated in cell growth and differentiation. STAT activation is regulated by phosphorylation of protein monomers at conserved tyrosine residues, followed by binding to phospho-peptide pockets and subsequent dimerization. STAT5 is implicated in the development of severe pathological conditions, including many cancer forms. However, nowadays a few STAT5 inhibitors are known, and only one crystal structure of the inactive STAT5 dimer is publicly available. With a view to enabling structure-based drug design, we have: (1) analyzed phospho-peptide binding pockets on SH2 domains of STAT5, STAT1 and STAT3; (2) generated a model of STAT5 bound to phospho-peptides; (3) assessed our model by docking against a class of known STAT5 inhibitors (Müller et al. in ChemBioChem 9:723-727, 2008); (4) used molecular dynamics simulations to optimize the molecular determinants responsible for binding and (5) proposed unique "Binding Signatures" of STAT5. Our results put in place the foundations to address STAT5 as a target for rational drug design, from sequence, structural and functional perspectives.
Similar articles
-
Exploring dual inhibitors for STAT1 and STAT5 receptors utilizing virtual screening and dynamics simulation validation.J Biomol Struct Dyn. 2016 Oct;34(10):2115-29. doi: 10.1080/07391102.2015.1108870. Epub 2015 Nov 30. J Biomol Struct Dyn. 2016. PMID: 26471877
-
Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization.Sci Rep. 2016 Oct 18;6:35454. doi: 10.1038/srep35454. Sci Rep. 2016. PMID: 27752093 Free PMC article.
-
In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.Eur J Pharmacol. 2013 Nov 15;720(1-3):38-48. doi: 10.1016/j.ejphar.2013.10.055. Epub 2013 Nov 6. Eur J Pharmacol. 2013. PMID: 24211327
-
A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. doi: 10.1517/13543776.2015.1086749. Epub 2015 Sep 22. Expert Opin Ther Pat. 2015. PMID: 26394986 Review.
-
Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation.Front Biosci (Landmark Ed). 2011 Jun 1;16(8):3043-56. doi: 10.2741/3897. Front Biosci (Landmark Ed). 2011. PMID: 21622220 Review.
Cited by
-
The transcription factor STAT5 catalyzes Mannich ligation reactions yielding inhibitors of leukemic cell proliferation.Nat Commun. 2019 Jan 8;10(1):66. doi: 10.1038/s41467-018-07923-2. Nat Commun. 2019. PMID: 30622248 Free PMC article.
-
How Intrinsic Molecular Dynamics Control Intramolecular Communication in Signal Transducers and Activators of Transcription Factor STAT5.PLoS One. 2015 Dec 30;10(12):e0145142. doi: 10.1371/journal.pone.0145142. eCollection 2015. PLoS One. 2015. PMID: 26717567 Free PMC article.
-
Computational analysis of EBNA1 "druggability" suggests novel insights for Epstein-Barr virus inhibitor design.J Comput Aided Mol Des. 2016 Apr;30(4):285-303. doi: 10.1007/s10822-016-9899-y. Epub 2016 Apr 5. J Comput Aided Mol Des. 2016. PMID: 27048620 Free PMC article.
-
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo.Nat Chem Biol. 2023 Jun;19(6):703-711. doi: 10.1038/s41589-022-01248-4. Epub 2023 Feb 2. Nat Chem Biol. 2023. PMID: 36732620
-
The structural influence of the oncogenic driver mutation N642H in the STAT5B SH2 domain.Protein Sci. 2025 Jan;34(1):e70022. doi: 10.1002/pro.70022. Protein Sci. 2025. PMID: 39723827 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous